Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity

Editor, Vascular endothelial growth factor (VEGF) is considered to be the major growth factor mediating retinal vascularization in retinopathy of prematurity (ROP). Intravitreal anti-VEGF treatment with bevacizumab has been shown to be effective in treating ROP in the BEAT-ROP trial (Mintz-Hittner e...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Robert Hoerster, Philipp S. Muether, Claudia Dahlke, Katrin Mehler, André Oberthür, Bernd Kirchhof, Sascha Fauser
Aineistotyyppi: Carta
Kieli:englanti
Julkaistu: 2012
Linkit:https://doi.org/10.1111/j.1755-3768.2012.02469.x
https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1755-3768.2012.02469.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!